Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Hoeper MM, Andreas S, Bastian A, Claussen M, Ghofrani HA, Gorenflo M, Grohé C, Günther A, Halank M, Hammerl P, Held M, Krüger S, Lange TJ, Reichenberger F, Sablotzki A, Staehler G, Stark W, Wirtz H, Witt C, Behr J. Pulmonary hypertension due to chronic lung disease: updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 2012;154 Suppl 1:S45-53. [PMID: 22221973 DOI: 10.1016/s0167-5273(11)70492-2] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]

For:	Hoeper MM, Andreas S, Bastian A, Claussen M, Ghofrani HA, Gorenflo M, Grohé C, Günther A, Halank M, Hammerl P, Held M, Krüger S, Lange TJ, Reichenberger F, Sablotzki A, Staehler G, Stark W, Wirtz H, Witt C, Behr J. Pulmonary hypertension due to chronic lung disease: updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 2012;154 Suppl 1:S45-53. [PMID: 22221973 DOI: 10.1016/s0167-5273(11)70492-2] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]

Number

Cited by Other Article(s)

Jambon-Barbara C, Hlavaty A, Bernardeau C, Bouvaist H, Chaumais MC, Humbert M, Montani D, Cracowski JL, Khouri C. Development and validation of a code-based algorithm using in-hospital medical records to identify patients with pulmonary arterial hypertension in a French healthcare database. ERJ Open Res 2024;10:00109-2024. [PMID: 39135662 PMCID: PMC11317892 DOI: 10.1183/23120541.00109-2024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2024] [Accepted: 04/11/2024] [Indexed: 08/15/2024] Open

Abstract

Introduction

Pulmonary arterial hypertension (PAH) is a rare and severe disease for which most of the evidence about prognostic factors, evolution and treatment efficacy comes from cohorts, registries and clinical trials. We therefore aimed to develop and validate a new PAH identification algorithm that can be used in the French healthcare database "Système National des Données de Santé (SNDS)".

Methods

We developed and validated the algorithm using the Grenoble Alpes University Hospital medical charts. We first identified PAH patients following a previously validated algorithm, using in-hospital ICD-10 (10th revision of the International Statistical Classification of Diseases) codes, right heart catheterisation procedure and PAH-specific treatment dispensing. Then, we refined the latter with the exclusion of chronic thromboembolic pulmonary hypertension procedures and treatment, the main misclassification factor. Second, we validated this algorithm using a gold standard review of in-hospital medical charts and calculated sensitivity, specificity, positive and negative predictive value (PPV and NPV) and accuracy. Finally, we applied this algorithm in the French healthcare database and described the characteristics of the identified patients.

Results

In the Grenoble University Hospital, we identified 252 unique patients meeting all the algorithm's criteria between 1 January 2010 and 30 June 2022, and reviewed all medical records. The sensitivity, specificity, PPV, NPV and accuracy were 91.0%, 74.3%, 67.9%, 93.3% and 80.6%, respectively. Application of this algorithm to the SNDS yielded the identification of 9931 patients with consistent characteristics compared to PAH registries.

Conclusion

Overall, we propose a new PAH identification algorithm developed and adapted to the French specificities that can be used in future studies using the French healthcare database.

Collapse

Affiliation(s)

Clément Jambon-Barbara Pharmacovigilance Unit, Grenoble Alpes University Hospital, Grenoble, France Univ. Grenoble Alpes, HP2 Laboratory, Inserm U1300, Grenoble, France
Alex Hlavaty Pharmacovigilance Unit, Grenoble Alpes University Hospital, Grenoble, France Univ. Grenoble Alpes, HP2 Laboratory, Inserm U1300, Grenoble, France
Claire Bernardeau Pharmacovigilance Unit, Grenoble Alpes University Hospital, Grenoble, France
Hélène Bouvaist Cardiology Unit, Grenoble Alpes University Hospital, Grenoble, France
Marie-Camille Chaumais INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Pharmacy, Hôpital Bicêtre, Le Kremlin-Bicêtre, France Faculty of Pharmacy, Université Paris-Saclay, Saclay, France
Marc Humbert INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France Faculty of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France AP-HP, Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Centre, Hôpital Bicêtre, DMU 5 Thorinno, Le Kremlin-Bicêtre, France
David Montani INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France Faculty of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France AP-HP, Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Centre, Hôpital Bicêtre, DMU 5 Thorinno, Le Kremlin-Bicêtre, France
Jean-Luc Cracowski Pharmacovigilance Unit, Grenoble Alpes University Hospital, Grenoble, France Univ. Grenoble Alpes, HP2 Laboratory, Inserm U1300, Grenoble, France
Charles Khouri Pharmacovigilance Unit, Grenoble Alpes University Hospital, Grenoble, France Univ. Grenoble Alpes, HP2 Laboratory, Inserm U1300, Grenoble, France Grenoble Alpes University Hospital, Clinical Pharmacology Department INSERM CIC1406, Grenoble, France

Collapse

Khan S, Randhawa S, Patail H, Spira Y, Frishman WH, Aronow WS, Lanier GM. Pharmacological Update and Emerging Treatments of Pulmonary Hypertension. Cardiol Rev 2024:00045415-990000000-00192. [PMID: 38294225 DOI: 10.1097/crd.0000000000000647] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2024]

Ling WHI, Wong CF, Yan SW, Fan YYK, Wong KL. The hemodynamic characteristics of severe chronic lung disease referred for lung transplantation. Pulm Circ 2022;12:e12082. [PMID: 35864910 PMCID: PMC9294294 DOI: 10.1002/pul2.12082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/08/2022] [Revised: 03/07/2022] [Accepted: 04/11/2022] [Indexed: 11/09/2022] Open

Luca E, Bodrug N. The frequency of pulmonary hypertension in chronic obstructive pulmonary disease of geriatric patients: a narrative literature review. THE EGYPTIAN JOURNAL OF INTERNAL MEDICINE 2022. [DOI: 10.1186/s43162-022-00135-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open

Abstract Abstract Background Pulmonary hypertension (PH) is a serious complication with complex pathogenesis in the natural history of chronic obstructive pulmonary disease COPD, with a progressively increasing frequency with a meanwhile decreasing in functional capacity. Purpose Assessment of the incidence, pathogenesis, peculiarities, and complications of PH in COPD in geriatric population worldwide. Methods We performed an analysis of randomized, retrospective, and prospective clinical, case-control and observational studies, published at the international level, according to the subject studied and target population. Four hundred ninety-seven full articles were identified after the search through engine Google Search and databases PubMed, Hinari, SpringerLink, and Scopus (Elsevier) according to the keywords and subsequent filters. Results Depending on various factors, like the population examined, the definition used for mPAP (mPAP> 20 mm Hg or ≥25 mm Hg), the severity of the lung disease, and the method of measuring PAP, a varied incidence of COPD patients with PH complication was discovered, namely 10–91%. PH prevalence increases with the COPD severity. The presence of PH is associated with acute exacerbations of COPD, reduced survival, and increasing expenses for healthcare programs. Mild to moderate levels of PH (mPAP 25–34 mm Hg) are relatively common in COPD and usually are associated with severe airflow obstruction or parenchymal destruction. Only a minority of patients (1–5%) have severe PH (mPAP ≥35 mm Hg). Conclusions Diagnosis of PH in COPD is difficult, especially in a mild form, and requires a clinical approach associated with a comprehensive set of investigations for confirming the etiology, evaluation of the functional and hemodynamical impairment severity, and important factors in the appropriate treatment election. Collapse

Singh N, Dorfmüller P, Shlobin OA, Ventetuolo CE. Group 3 Pulmonary Hypertension: From Bench to Bedside. Circ Res 2022;130:1404-1422. [PMID: 35482836 PMCID: PMC9060386 DOI: 10.1161/circresaha.121.319970] [Citation(s) in RCA: 37] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]

Alkhanfar D, Shahin Y, Alandejani F, Dwivedi K, Alabed S, Johns C, Lawrie A, Thompson AAR, Rothman AMK, Tschirren J, Uthoff JM, Hoffman E, Condliffe R, Wild JM, Kiely DG, Swift AJ. Severe pulmonary hypertension associated with lung disease is characterised by a loss of small pulmonary vessels on quantitative computed tomography. ERJ Open Res 2022;8:00503-2021. [PMID: 35586449 PMCID: PMC9108962 DOI: 10.1183/23120541.00503-2021] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2021] [Accepted: 02/10/2022] [Indexed: 11/28/2022] Open

Affiliation(s)

Dheyaa Alkhanfar Dept of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.,INSIGNEO, Institute for In Silico Medicine, University of Sheffield, Sheffield, UK
Yousef Shahin Dept of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.,Dept of Clinical Radiology, Sheffield Teaching Hospitals, Sheffield, UK
Faisal Alandejani Dept of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
Krit Dwivedi Dept of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
Samer Alabed Dept of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.,Dept of Clinical Radiology, Sheffield Teaching Hospitals, Sheffield, UK
Chris Johns Dept of Clinical Radiology, Sheffield Teaching Hospitals, Sheffield, UK
Allan Lawrie Dept of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
A A Roger Thompson Dept of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.,Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
Alexander M K Rothman Dept of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.,Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
Juerg Tschirren VIDA Diagnostics Inc., Coralville, IA, USA
Johanna M Uthoff Dept of Computer Science, University of Sheffield, Sheffield, UK
Eric Hoffman Dept of Radiology, University of Iowa, Iowa City, IA, USA
Robin Condliffe Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
Jim M Wild Dept of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.,INSIGNEO, Institute for In Silico Medicine, University of Sheffield, Sheffield, UK
David G Kiely INSIGNEO, Institute for In Silico Medicine, University of Sheffield, Sheffield, UK.,Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.,These authors contributed equally
Andrew J Swift Dept of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.,INSIGNEO, Institute for In Silico Medicine, University of Sheffield, Sheffield, UK.,These authors contributed equally

Collapse

Jiang R, Wang L, Zhao QH, Wu C, Yuan P, Wang S, Zhang R, Gong SG, Wu WH, He J, Qiu HL, Luo CJ, Liu JM, Jing ZC. Echocardiography Nomogram for Predicting Survival among Chronic Lung Disease Patients with Severe Pulmonary Hypertension. J Clin Med 2022;11:jcm11061603. [PMID: 35329931 PMCID: PMC8955171 DOI: 10.3390/jcm11061603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2022] [Revised: 02/12/2022] [Accepted: 03/12/2022] [Indexed: 12/03/2022] Open

Affiliation(s)

Rong Jiang Department of Cardiopulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China; (R.J.); (L.W.); (Q.-H.Z.); (P.Y.); (S.W.); (R.Z.); (S.-G.G.); (W.-H.W.); (J.H.); (H.-L.Q.); (C.-J.L.); (J.-M.L.)
Lan Wang Department of Cardiopulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China; (R.J.); (L.W.); (Q.-H.Z.); (P.Y.); (S.W.); (R.Z.); (S.-G.G.); (W.-H.W.); (J.H.); (H.-L.Q.); (C.-J.L.); (J.-M.L.)
Qin-Hua Zhao Department of Cardiopulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China; (R.J.); (L.W.); (Q.-H.Z.); (P.Y.); (S.W.); (R.Z.); (S.-G.G.); (W.-H.W.); (J.H.); (H.-L.Q.); (C.-J.L.); (J.-M.L.)
Cheng Wu Department of Health Statistics, Naval Medical University, 800 Xiangyin Road, Shanghai 200433, China;
Ping Yuan Department of Cardiopulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China; (R.J.); (L.W.); (Q.-H.Z.); (P.Y.); (S.W.); (R.Z.); (S.-G.G.); (W.-H.W.); (J.H.); (H.-L.Q.); (C.-J.L.); (J.-M.L.)
Shang Wang Department of Cardiopulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China; (R.J.); (L.W.); (Q.-H.Z.); (P.Y.); (S.W.); (R.Z.); (S.-G.G.); (W.-H.W.); (J.H.); (H.-L.Q.); (C.-J.L.); (J.-M.L.)
Rui Zhang Department of Cardiopulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China; (R.J.); (L.W.); (Q.-H.Z.); (P.Y.); (S.W.); (R.Z.); (S.-G.G.); (W.-H.W.); (J.H.); (H.-L.Q.); (C.-J.L.); (J.-M.L.)
Su-Gang Gong Department of Cardiopulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China; (R.J.); (L.W.); (Q.-H.Z.); (P.Y.); (S.W.); (R.Z.); (S.-G.G.); (W.-H.W.); (J.H.); (H.-L.Q.); (C.-J.L.); (J.-M.L.)
Wen-Hui Wu Department of Cardiopulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China; (R.J.); (L.W.); (Q.-H.Z.); (P.Y.); (S.W.); (R.Z.); (S.-G.G.); (W.-H.W.); (J.H.); (H.-L.Q.); (C.-J.L.); (J.-M.L.)
Jing He Department of Cardiopulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China; (R.J.); (L.W.); (Q.-H.Z.); (P.Y.); (S.W.); (R.Z.); (S.-G.G.); (W.-H.W.); (J.H.); (H.-L.Q.); (C.-J.L.); (J.-M.L.)
Hong-Ling Qiu Department of Cardiopulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China; (R.J.); (L.W.); (Q.-H.Z.); (P.Y.); (S.W.); (R.Z.); (S.-G.G.); (W.-H.W.); (J.H.); (H.-L.Q.); (C.-J.L.); (J.-M.L.)
Ci-Jun Luo Department of Cardiopulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China; (R.J.); (L.W.); (Q.-H.Z.); (P.Y.); (S.W.); (R.Z.); (S.-G.G.); (W.-H.W.); (J.H.); (H.-L.Q.); (C.-J.L.); (J.-M.L.)
Jin-Ming Liu Department of Cardiopulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China; (R.J.); (L.W.); (Q.-H.Z.); (P.Y.); (S.W.); (R.Z.); (S.-G.G.); (W.-H.W.); (J.H.); (H.-L.Q.); (C.-J.L.); (J.-M.L.)
Zhi-Cheng Jing Department of Cardiopulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China; (R.J.); (L.W.); (Q.-H.Z.); (P.Y.); (S.W.); (R.Z.); (S.-G.G.); (W.-H.W.); (J.H.); (H.-L.Q.); (C.-J.L.); (J.-M.L.) Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, 1 Shuai-Fu-Yuan, Dongcheng District, Beijing 100730, China Correspondence:

Collapse

Wang L, Shen L, Zhao YL, Pudasaini B, Zhao QH, Gong SG, Zhang R, Yuan P, He J, Luo CJ, Qiu HL, Liu JM, Jiang R. Survival in severe pulmonary hypertension due to chronic lung disease: influence of in-hospital platelet distribution width. Pulm Circ 2021;11:20458940211026484. [PMID: 34276962 PMCID: PMC8258768 DOI: 10.1177/20458940211026484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/29/2020] [Accepted: 05/29/2021] [Indexed: 11/22/2022] Open

Saeed ZH, Magdy MH, Abdelnaem EA, Mahmoud MM. Serum Krebs von den Lungen (KL-6) level as a marker of exacerbation of interstitial lung diseases. THE EGYPTIAN JOURNAL OF BRONCHOLOGY 2020. [DOI: 10.1186/s43168-020-00043-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open

Gredic M, Blanco I, Kovacs G, Helyes Z, Ferdinandy P, Olschewski H, Barberà JA, Weissmann N. Pulmonary hypertension in chronic obstructive pulmonary disease. Br J Pharmacol 2020;178:132-151. [PMID: 31976545 DOI: 10.1111/bph.14979] [Citation(s) in RCA: 51] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2019] [Revised: 12/29/2019] [Accepted: 01/06/2020] [Indexed: 12/12/2022] Open

Kovacs G, Agusti A, Barberà JA, Celli B, Criner G, Humbert M, Sin DD, Voelkel N, Olschewski H. Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype? Am J Respir Crit Care Med 2019;198:1000-1011. [PMID: 29746142 DOI: 10.1164/rccm.201801-0095pp] [Citation(s) in RCA: 124] [Impact Index Per Article: 20.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open

Darwiche T, Collum SD, Bi W, Reynolds JO, Wilson C, Wareing N, Hernandez AM, Mertens TCJ, Zhou Z, Pandit LM, Karmouty-Quintana H. Alterations in cardiovascular function in an experimental model of lung fibrosis and pulmonary hypertension. Exp Physiol 2019;104:568-579. [PMID: 30663834 DOI: 10.1113/ep087321] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2018] [Accepted: 01/18/2019] [Indexed: 01/02/2023]

Abstract

NEW FINDINGS

What is the central question of this study? We have evaluated changes in cardiovascular physiology using echocardiography in an experimental model of lung fibrosis. What is the main finding and its importance? Remarkably, we report changes in cardiovascular function as early as day 7, concomitant with evidence of vascular remodelling. We also report that isolated pulmonary arteries were hypercontractile in response to a thromboxane A2 agonist. These findings are significant because the development of pulmonary hypertension is one of the most significant predictors of mortality in patients with lung fibrosis, where there are no available therapies and a lack of animal models.

ABSTRACT

Group III pulmonary hypertension is observed in patients with chronic lung diseases such as chronic obstructive pulmonary disease or idiopathic pulmonary fibrosis. Pulmonary hypertension (PH) develops as a result of extensive pulmonary vascular remodelling and resultant changes in vascular tone that can lead to right ventricle hypertrophy. This eventually leads to right heart failure, which is the leading indicator of mortality in patients with idiopathic pulmonary fibrosis. Treatments for group III PH are not available, in part owing to a lack of viable animal models. Here, we have evaluated the cardiovascular changes in a model of lung fibrosis and PH. Data obtained from this study indicated that structural alterations in the right heart, such as right ventricular wall hypertrophy, occurred as early as day 14, and similar increases in right ventricle chamber size were seen between days 21 and 28. These structural changes were correlated with decreases in the systolic function of the right ventricle and right ventricular cardiac output, which also occurred between the same time points. Characterization of pulmonary artery dynamics also highlighted that PH might be occurring as early as day 21, indicated by reductions in the velocity-time integral; however, evidence for PH is apparent as early as day 7, indicated by the significant reduction in pulmonary acceleration time values. These changes are consistent with evidence of vascular remodelling observed histologically starting on day 7. In addition, we report hyperactivity of bleomycin-exposed pulmonary arteries to a thromboxane A2 receptor (Tbxa2r) agonist.

Collapse

Jeon CH. Early Detection of Pulmonary Hypertension in Connective Tissue Disease. JOURNAL OF RHEUMATIC DISEASES 2019. [DOI: 10.4078/jrd.2019.26.1.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]

Wang L, Jin YZ, Zhao QH, Jiang R, Wu WH, Gong SG, He J, Liu JM, Jing ZC. Hemodynamic and gas exchange effects of inhaled iloprost in patients with COPD and pulmonary hypertension. Int J Chron Obstruct Pulmon Dis 2017;12:3353-3360. [PMID: 29200842 PMCID: PMC5702173 DOI: 10.2147/copd.s141798] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open

Gall H, Felix JF, Schneck FK, Milger K, Sommer N, Voswinckel R, Franco OH, Hofman A, Schermuly RT, Weissmann N, Grimminger F, Seeger W, Ghofrani HA. The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups. J Heart Lung Transplant 2017;36:957-967. [DOI: 10.1016/j.healun.2017.02.016] [Citation(s) in RCA: 233] [Impact Index Per Article: 29.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2016] [Revised: 02/09/2017] [Accepted: 02/15/2017] [Indexed: 11/29/2022] Open

Memon HA, Lin CH, Guha A. Chronic Thromboembolic Pulmonary Hypertension: Pearls and Pitfalls of Diagnosis. Methodist Debakey Cardiovasc J 2017;12:199-204. [PMID: 28289494 DOI: 10.14797/mdcj-12-4-199] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open

Jiang R, Wu C, Pudasaini B, Wang L, Zhao QH, Zhang R, Wu WH, Yuan P, Jing ZC, Liu JM. A novel scoring index by Doppler echocardiography for predicting severe pulmonary hypertension due to chronic lung diseases: a cross-sectional diagnostic accuracy study. Int J Chron Obstruct Pulmon Dis 2017;12:1741-1751. [PMID: 28652726 PMCID: PMC5476678 DOI: 10.2147/copd.s133854] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open

Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis: Current and Future Perspectives. Can Respir J 2017;2017:1430350. [PMID: 28286407 PMCID: PMC5327768 DOI: 10.1155/2017/1430350] [Citation(s) in RCA: 51] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2016] [Accepted: 01/19/2017] [Indexed: 12/12/2022] Open

Panagiotou M, Church AC, Johnson MK, Peacock AJ. Pulmonary vascular and cardiac impairment in interstitial lung disease. Eur Respir Rev 2017;26:26/143/160053. [PMID: 28096284 PMCID: PMC9488566 DOI: 10.1183/16000617.0053-2016] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2016] [Accepted: 08/02/2016] [Indexed: 12/19/2022] Open

Pulmonary Hypertension: Scientometric Analysis and Density-Equalizing Mapping. PLoS One 2017;12:e0169238. [PMID: 28052133 PMCID: PMC5215006 DOI: 10.1371/journal.pone.0169238] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2015] [Accepted: 12/12/2016] [Indexed: 12/12/2022] Open

Abstract

Pulmonary hypertension (PH) is characterized by the increase of the mean pulmonary arterial pressure in the lung circulation. Despite the large number of experimental and clinical studies conducted on pulmonary hypertension, there is no comprehensive work that analyzed the global research activity on PH so far. We retrieved the bibliometric data of the publications on pulmonary hypertension for two periods from the Web of science database. Here, we set the first investigation period from 1900 to 2007 (t1) due to the cited half life of articles and the relating difficulties to interpret the citation parameters. The second evaluation period (t2) covers the time interval from 2008 onwards including the year 2015. The data were analyzed and processed to density-equalizing maps using the NewQIS platform. A total number of 18,986 publications were identified in t1 that come from 85 countries. The US published the highest number of publications (n = 7,290), followed by the UK, Germany, Japan and France. In t2 19,676 items could be found worked out by 130 countries. The raking started just the same with the USA as most publishing nation with 7,127 publications on PH, followed by the UK and Germany. Japan fell back on 6^th place, whereas China came into view on the 5^th position. Analyzing the average citation rate as a parameter for research quality, Mexico reached the highest value in t1 and Ireland in t2. While, the country specific h-index underlined the leading position of the US research in both evaluation periods again. The average number of international collaboration items was expanding from none in 1978 to 530 items in 2015 with the USA as the country with the highest number of collaboration articles. The present study is the first large scale density-equalizing mapping and scientometric analysis of global PH research activity. Our data draw a sketch of the global research architecture in this field, indicating a need for specific research programs in countries with a lower human development index.

Collapse

Kadmon G, Schiller O, Dagan T, Bruckheimer E, Birk E, Schonfeld T. Pulmonary hypertension specific treatment in infants with bronchopulmonary dysplasia. Pediatr Pulmonol 2017;52:77-83. [PMID: 27333438 DOI: 10.1002/ppul.23508] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/24/2016] [Revised: 05/15/2016] [Accepted: 06/08/2016] [Indexed: 11/05/2022]

Sulfur Mustard Exposure and Cardiovascular Effects: A Review. Trauma Mon 2016. [DOI: 10.5812/traumamon.34011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open

Ju CR, Zhang JH, Chen M, Chen RC. Plasma myostatin levels are related to the extent of right ventricular dysfunction in exacerbation of chronic obstructive pulmonary disease. Biomarkers 2016;22:246-252. [PMID: 27323660 DOI: 10.1080/1354750x.2016.1203999] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]

Hoeper MM, Behr J, Held M, Grunig E, Vizza CD, Vonk-Noordegraaf A, Lange TJ, Claussen M, Grohé C, Klose H, Olsson KM, Zelniker T, Neurohr C, Distler O, Wirtz H, Opitz C, Huscher D, Pittrow D, Gibbs JSR. Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias. PLoS One 2015;10:e0141911. [PMID: 26630396 PMCID: PMC4667900 DOI: 10.1371/journal.pone.0141911] [Citation(s) in RCA: 75] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2015] [Accepted: 10/14/2015] [Indexed: 01/04/2023] Open

Affiliation(s)

Marius M. Hoeper Department of Respiratory Medicine and German Center of Lung Research (DZL), Hannover Medical School, Hannover, Germany * E-mail:
Juergen Behr Department of Internal Medicine V, University of Munich, Munich, Germany
Matthias Held Department of Internal Medicine, Respiratory Medicine and Cardiology, Mission Medical Hospital, Würzburg, Germany
Ekkehard Grunig University Hospital Heidelberg, Heidelberg, Germany
C. Dario Vizza Department of Cardiovascular and Respiratory Diseases, Sapienza, University of Rome, Rome, Italy
Anton Vonk-Noordegraaf Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands
Tobias J. Lange Department of Internal Medicine II, Division of Pneumology, University Medical Center Regensburg, Regensburg, Germany
Martin Claussen LungenClinic, Grosshansdorf, Germany
Christian Grohé Department of Respiratory Medicine, ELK Thorax Centre, Berlin, Germany
Hans Klose University Medical Center Hamburg-Eppendorf, Center of Oncology, Department of Respiratory Medicine, Hamburg, Germany
Karen M. Olsson Department of Respiratory Medicine and German Center of Lung Research (DZL), Hannover Medical School, Hannover, Germany
Thomas Zelniker Department of Cardiology, Angiology and Pneumology, University of Heidelberg, Heidelberg, Germany
Claus Neurohr Department of Internal Medicine V, University of Munich, Munich, Germany
Oliver Distler Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Hubert Wirtz Department of Respiratory Medicine, University of Leipzig, Leipzig, Germany
Christian Opitz Department of Cardiology, DRK Kliniken Berlin Köpenick, Berlin, Germany
Doerte Huscher Department of Rheumatology and Clinical Immunology, Charité University Hospital, and Epidemiology unit, German Rheumatism Research Centre, Berlin, Germany
David Pittrow Institute for Clinical Pharmacology, Medical Faculty, Technical University, Dresden, Germany
J. Simon R. Gibbs Department of Cardiology, National Heart & Lung Institute; Imperial College London, London, United Kingdom

Collapse

Papathanasiou A, Nakos G. Why there is a need to discuss pulmonary hypertension other than pulmonary arterial hypertension? World J Crit Care Med 2015;4:274-277. [PMID: 26557477 PMCID: PMC4631872 DOI: 10.5492/wjccm.v4.i4.274] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/25/2015] [Revised: 08/11/2015] [Accepted: 09/16/2015] [Indexed: 02/06/2023] Open

Abstract

Pulmonary hypertension (PH) is a condition characterized by the elevation of the mean pulmonary artery pressure above 25 mmHg and the pulmonary vascular resistance above 3 wood units. Pulmonary arterial hypertension (PAH) is an uncommon condition with severe morbidity and mortality, needing early recognition and appropriate and specific treatment. PH is frequently associated with hypoxemia, mainly chronic obstructive pulmonary disease and DPLD and/or left heart diseases (LHD), mainly heart failure with reduced or preserved ejection fraction. Although in the majority of patients with PH the cause is not PAH, a significant number of published studies are still in regard to group I PH, leading to a logical assumption that PH due to other causes is not such an important issue. So, is there a reason to discuss PH other than PAH? Chronic lung diseases, mainly chronic obstructive lung disease and DPLD, are associated with a high incidence of PH which is linked to exercise limitations and a worse prognosis. Although pathophysiological studies suggest that specific PAH therapy may benefit such patients, the results presented from small studies in regard to the safety and effectiveness of the specific PAH therapy are discouraging. PH is a common complication of left heart disease and is related to disease severity, especially in patients with reduced ejection fraction. There are two types of PH related to LHD based on diastolic pressure difference (DPD, deﬁned as diastolic pulmonary artery pressure - mean PAWP): Isolated post-capillary PH, defined as PAWP > 15 mmHg and DPD < 7 mmHg, and combined post-capillary PH and pre-capillary PH, defined as PAWP > 15 mmHg and DPD ≥ 7 mmHg. The potential use of PAH therapies in patients with PH related to left heart disease is based on a logical pathobiological rationale. In patients with heart failure, endothelial dysfunction has been proposed as a cause of PH and hence as a target for treatment, supported by the presence of increased endothelin-1 activity and impaired nitric oxide-dependent vasodilation. Unfortunately, so far, there is no evidence supporting the use of specific PAH therapies in patients with PH related to left heart disease. In conclusion, the presence of PH in patients with conditions other than PAH contributes to the severity of the disease, affecting the outcome and quality of life. The disappointing results regarding the effectiveness of specific PAH therapies in patients with chronic lung diseases and LHD underline the need for seeking new underlying mechanisms and thus novel therapies targeting PH due to left heart disease and/or lung diseases.

Collapse

Beghetti M, Schulze-Neick I, Berger RMF, Ivy DD, Bonnet D, Weintraub RG, Saji T, Yung D, Mallory GB, Geiger R, Berger JT, Barst RJ, Humpl T. Haemodynamic characterisation and heart catheterisation complications in children with pulmonary hypertension: Insights from the Global TOPP Registry (tracking outcomes and practice in paediatric pulmonary hypertension). Int J Cardiol 2015;203:325-30. [PMID: 26583838 DOI: 10.1016/j.ijcard.2015.10.087] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/05/2015] [Revised: 09/04/2015] [Accepted: 10/12/2015] [Indexed: 02/01/2023]

Lange TJ, Baron M, Seiler I, Arzt M, Pfeifer M. Outcome of patients with severe PH due to lung disease with and without targeted therapy. Cardiovasc Ther 2015;32:202-8. [PMID: 24909193 DOI: 10.1111/1755-5922.12084] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open

Abstract

INTRODUCTION

Pulmonary hypertension (PH) can occur in patients with lung disease and worsen prognosis. Endothelin receptor antagonists, phosphodiesterase 5-inhibitors, and prostacyclin analogs, referred to as targeted therapy, have not been shown in a limited number of controlled clinical studies to improve exercise capacity in these patients. Possibly targeted therapy could be of benefit in patients with severe PH due to lung disease, but this subgroup is not well studied.

AIMS

To analyze influence of PH severity and use of targeted therapy on exercise capacity and survival in patients with PH due to lung disease.

METHODS

Consecutive patients with PH (mean pulmonary artery pressure ≥25 mmHg at rest) due to lung disease diagnosed by right heart catheterization between 1/2005 and 9/2011 were retrospectively included. Severe PH was defined as mean pulmonary artery pressure ≥35 mmHg. Patients were followed until 4/2012 for exercise capacity, survival, and targeted therapy use.

RESULTS

Patients with severe PH (n = 40) received significantly more often targeted therapy compared to the 32 patients with less severe PH (65% vs. 25%, P = 0.001). Survival was not significantly different between these groups (P = 0.310). Patients on targeted therapy were older, more often female, and had worse hemodynamic impairment, but significantly higher estimated 1-, 3-, and 5-year survival rates compared to untreated patients (97%, 81%, and 75% vs. 83%, 54%, and 19%, respectively; P = 0.002). This effect was mainly driven by the patients with severe PH, in whom the survival advantage was statistically significant on subgroup analysis (HR 0.182, P = 0.002). Exercise capacity was not significantly altered in any patient group.

CONCLUSION

Patients with severe PH due to lung disease may have a survival benefit from targeted therapy compared to untreated patients with less severe PH. Prospective clinical trials utilizing targeted therapy and long-term endpoints are justified in this patient group.

Collapse

Bandorski D, Erkapic D, Stempfl J, Höltgen R, Grünig E, Schmitt J, Chasan R, Grimminger J, Neumann T, Hamm CW, Seeger W, Ghofrani HA, Gall H. Ventricular tachycardias in patients with pulmonary hypertension: an underestimated prevalence? A prospective clinical study. Herzschrittmacherther Elektrophysiol 2015;26:155-162. [PMID: 26031512 DOI: 10.1007/s00399-015-0364-8] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2015] [Accepted: 03/10/2015] [Indexed: 06/04/2023]

Abstract

BACKGROUND

Sudden cardiac death (SCD) accounts for approximately 30 % in patients with pulmonary arterial hypertension (PAH). The exact circumference for SCD in this patient population is still unclear. Malignant cardiac arrhythmias are reported to be rarely present. There are no systematic data concerning long-term electrocardiographic (ECG) recording in patients with PAH.

OBJECTIVES

We sought to investigate the rate of potentially relevant arrhythmias in patients with pulmonary hypertension (PH).

METHODS

Consecutive patients without diagnosis of known cardiac arrhythmias followed in our outpatient clinic for PH were enrolled in the study. All patients underwent a 72-h Holter ECG. Clinical data, 6-min walk distance, laboratory values, and echocardiography were collected/performed.

RESULTS

Ninety-two consecutive patients (New York Heart Association class (NYHA) III/IV: 65.2 %/5.4 %, PH Group 1: 35.9 %, Group 3: 10.9 %, Group 4: 28.3 %, Group 5: 2.2 %) were investigated. Relevant arrhythmias were newly detected in 17 patients: non-sustained ventricular tachycardia (n = 12), intermittent second-degree heart block (n = 1), intermittent third-degree heart block (n= 3), and atrial flutter (n = 1). Echocardiographic systolic pulmonary pressure and diameter of the right heart were elevated in patients with relevant arrhythmias. Right heart catheterization revealed higher pulmonary vascular resistance (672 vs. 542 dyn · s · cm(-5), p = 0.247) and lower cardiac index (2.46 vs. 2.82 l/min/m(2), p = 0.184).

CONCLUSIONS

Ventricular tachycardias occur more often in PH patients than previously reported. However, the prognostic relevance of non-sustained ventricular tachycardias in this cohort remains unclear. As a large number of PH patients die from SCD, closer monitoring, e.g., using implantable event recorders, might be useful to identify patients at high risk.

Collapse

Behr J. The diagnosis and treatment of idiopathic pulmonary fibrosis. DEUTSCHES ARZTEBLATT INTERNATIONAL 2015;110:875-81. [PMID: 24529303 DOI: 10.3238/arztebl.2013.0875] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/29/2013] [Revised: 10/10/2013] [Accepted: 10/10/2013] [Indexed: 01/12/2023]

Abstract

BACKGROUND

Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial disease of the lung and has the worst prognosis of all such diseases, with a median survival time of three to four years. Its prevalence is 2-29 per 100,000 persons and its incidence approximately 10 per 100,000 persons per year, with an upward trend.

METHOD

Selective literature search in the EMBASE and PubMed databases for pertinent publications from 1996 to 2012, with special attention to randomized controlled trials.

RESULTS

IPF manifests itself clinically with exertional dyspnea, dry cough, and inspiratory crepitations (sclerosiphonia). The diagnosis is confirmed by the demonstration of a usual interstitial pneumonia (UIP) pattern in a high-resolution thin-slice CT (HRCT) of the lungs, or else histologically by lung biopsy, along with the exclusion of other causes such as asbestosis or connective tissue disease. In 15 randomized controlled therapeutic trials carried out since 2004, most of the drugs that were tested, including immune suppressants, were found to be ineffective against IPF or even harmful. Only pirfenidone lessens the annual reduction of pulmonary volume (FVC, forced expiratory vital capacity) and of the distance walked in 6 minutes by about 30%, with corresponding improvement of progression-free survival, but without any significant lessening of overall mortality (placebo, 10%; pirfenidone, 8%). Pirfenidone also commonly causes gastrointestinal and cutaneous side effects. The efficacy of N-acetyldysteine and nintedanib has not yet been definitively demonstrated. Lung transplantation is the only current treatment that enables long-term survival.

CONCLUSION

IPF has a worse prognosis than many types of cancer. Drugs can delay the progression of the disease but probably cannot bring it to a permanent standstill.

Collapse

Rosenkranz S. Pulmonary hypertension 2015: current definitions, terminology, and novel treatment options. Clin Res Cardiol 2014;104:197-207. [PMID: 25479818 DOI: 10.1007/s00392-014-0765-4] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/21/2014] [Accepted: 09/26/2014] [Indexed: 12/12/2022]

Eberhardt R, Gerovasili V, Kontogianni K, Gompelmann D, Ehlken N, Herth FJF, Grünig E, Nagel C. Endoscopic lung volume reduction with endobronchial valves in patients with severe emphysema and established pulmonary hypertension. ACTA ACUST UNITED AC 2014;89:41-8. [PMID: 25502235 DOI: 10.1159/000368369] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2014] [Accepted: 08/26/2014] [Indexed: 11/19/2022]

Lung transplantation for interstitial lung diseases. Curr Opin Pulm Med 2014;20:457-62. [DOI: 10.1097/mcp.0000000000000090] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]

Pulmonary hypertension and right heart dysfunction in chronic lung disease. BIOMED RESEARCH INTERNATIONAL 2014;2014:739674. [PMID: 25165714 PMCID: PMC4140123 DOI: 10.1155/2014/739674] [Citation(s) in RCA: 64] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/18/2014] [Revised: 06/24/2014] [Accepted: 06/29/2014] [Indexed: 11/30/2022]

Iyer AS, Wells JM, Vishin S, Bhatt SP, Wille KM, Dransfield MT. CT scan-measured pulmonary artery to aorta ratio and echocardiography for detecting pulmonary hypertension in severe COPD. Chest 2014;145:824-832. [PMID: 24114440 DOI: 10.1378/chest.13-1422] [Citation(s) in RCA: 143] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open

Zimmermann GS, von Wulffen W, Huppmann P, Meis T, Ihle F, Geiseler J, Leuchte HH, Tufman A, Behr J, Neurohr C. Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors. Respirology 2014;19:700-6. [DOI: 10.1111/resp.12294] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2013] [Revised: 12/11/2013] [Accepted: 01/29/2014] [Indexed: 01/30/2023]

Rosenkranz S. [Cor pulmonale and pulmonary hypertension. Update after the world conference in Nice]. Herz 2014;39:58-65. [PMID: 24638159 DOI: 10.1007/s00059-014-4058-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]

Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2014;62:D109-16. [PMID: 24355635 DOI: 10.1016/j.jacc.2013.10.036] [Citation(s) in RCA: 430] [Impact Index Per Article: 39.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/12/2013] [Accepted: 10/22/2013] [Indexed: 12/22/2022]

Abstract

Chronic obstructive lung disease (COPD) and diffuse parenchymal lung diseases (DPLD), including idiopathic pulmonary fibrosis (IPF) and sarcoidosis, are associated with a high incidence of pulmonary hypertension (PH), which is linked with exercise limitation and a worse prognosis. Patients with combined pulmonary fibrosis and emphysema (CPFE) are particularly prone to the development of PH. Echocardiography and right heart catheterization are the principal modalities for the diagnosis of COPD and DPLD. For discrimination between group 1 PH patients with concomitant respiratory abnormalities and group 3 PH patients (PH caused by lung disease), patients should be transferred to a center with expertise in both PH and lung diseases for comprehensive evaluation. The task force encompassing the authors of this article provided criteria for this discrimination and suggested using the following definitions for group 3 patients, as exemplified for COPD, IPF, and CPFE: COPD/IPF/CPFE without PH (mean pulmonary artery pressure [mPAP] <25 mm Hg); COPD/IPF/CPFE with PH (mPAP ≥25 mm Hg); PH-COPD, PH-IPF, and PH-CPFE); COPD/IPF/CPFE with severe PH (mPAP ≥35 mm Hg or mPAP ≥25 mm Hg with low cardiac index [CI <2.0 l/min/m(2)]; severe PH-COPD, severe PH-IPF, and severe PH-CPFE). The "severe PH group" includes only a minority of chronic lung disease patients who are suspected of having strong general vascular abnormalities (remodeling) accompanying the parenchymal disease and with evidence of an exhausted circulatory reserve rather than an exhausted ventilatory reserve underlying the limitation of exercise capacity. Exertional dyspnea disproportionate to pulmonary function tests, low carbon monoxide diffusion capacity, and rapid decline of arterial oxygenation upon exercise are typical clinical features of this subgroup with poor prognosis. Studies evaluating the effect of pulmonary arterial hypertension drugs currently not approved for group 3 PH patients should focus on this severe PH group, and for the time being, these patients should be transferred to expert centers for individualized patient care.

Collapse

Kauppert CA, Dvorak I, Kollert F, Heinemann F, Jörres RA, Pfeifer M, Budweiser S. Pulmonary hypertension in obesity-hypoventilation syndrome. Respir Med 2013;107:2061-70. [DOI: 10.1016/j.rmed.2013.09.017] [Citation(s) in RCA: 64] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/01/2013] [Revised: 09/10/2013] [Accepted: 09/19/2013] [Indexed: 12/20/2022]

Minai OA, Fessler H, Stoller JK, Criner GJ, Scharf SM, Meli Y, Nutter B, DeCamp MM. Clinical characteristics and prediction of pulmonary hypertension in severe emphysema. Respir Med 2013;108:482-90. [PMID: 24290900 DOI: 10.1016/j.rmed.2013.11.006] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/24/2013] [Revised: 10/28/2013] [Accepted: 11/08/2013] [Indexed: 10/26/2022]

Ganga HV, Nair SU, Puppala VK, Miller WL. Risk of new-onset atrial fibrillation in elderly patients with the overlap syndrome: a retrospective cohort study. J Geriatr Cardiol 2013;10:129-34. [PMID: 23888171 PMCID: PMC3708051 DOI: 10.3969/j.issn.1671-5411.2013.02.001] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2013] [Revised: 04/02/2013] [Accepted: 04/22/2013] [Indexed: 12/31/2022] Open

Four cases with group 3 out-of-proportion pulmonary hypertension with a favorable response to vasodilators. Respir Med Case Rep 2013;9:4-7. [PMID: 26029619 PMCID: PMC3949553 DOI: 10.1016/j.rmcr.2013.03.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2013] [Accepted: 03/08/2013] [Indexed: 11/20/2022] Open

Preston IR. Properly diagnosing pulmonary arterial hypertension. Am J Cardiol 2013;111:2C-9C. [PMID: 23558028 DOI: 10.1016/j.amjcard.2013.01.318] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]

Rivera-Lebron BN. Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis. ACTA ACUST UNITED AC 2013. [DOI: 10.21693/1933-088x-12.3.127] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]

Pulmonary hypertension in parenchymal lung disease. Pulm Med 2012;2012:684781. [PMID: 23094153 PMCID: PMC3474989 DOI: 10.1155/2012/684781] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2012] [Accepted: 09/07/2012] [Indexed: 01/23/2023] Open